Showing 161 - 180 results of 103,183 for search '(( a fold decrease ) OR ( 5 ((((ng decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 1.56s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165

    Anti-TNF Thioester Glucocorticoid Antibody–Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model by Christopher C. Marvin (1338228)

    Published 2024
    “…Mouse PK indicated that <b>6</b> is cleared 10-fold more rapidly than a first-generation GRM payload, resulting in 10-fold lower exposure and 3-fold decrease in Cmax. …”
  6. 166

    Anti-TNF Thioester Glucocorticoid Antibody–Drug Conjugate Fully Inhibits Inflammation with Minimal Effect on Systemic Corticosterone Levels in a Mouse Arthritis Model by Christopher C. Marvin (1338228)

    Published 2024
    “…Mouse PK indicated that <b>6</b> is cleared 10-fold more rapidly than a first-generation GRM payload, resulting in 10-fold lower exposure and 3-fold decrease in Cmax. …”
  7. 167

    A New Rotane Family:  Synthesis, Structure, Conformation, and Dynamics of [3.4]-, [4.4]-, [5.4]-, and [6.4]Rotane<sup>1</sup> by Lutz Fitjer (2466634)

    Published 1998
    “…At the same time their folding decreases, until in <b>8</b> they are close to planar. …”
  8. 168
  9. 169
  10. 170
  11. 171
  12. 172

    Forty-two receptors arranged in order of decreasing interaction with the full set of thirty-five drugs. by Thomas S. Ray (253767)

    Published 2010
    “…<p>The forty-two receptors are arranged in order of decreasing interaction with the full set of thirty-five drugs, based on the breadth statistics, B, B<sub>sq</sub>. and B<sub>exp</sub>. …”
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177
  18. 178
  19. 179

    VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival. by Aye M. Mon (5714912)

    Published 2018
    “…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
  20. 180